Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will join a virtual fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026, at 3 PM ET.

Rhea-AI Summary

Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will join a virtual fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026, at 3 PM ET. A live and replay webcast will be available on the investor relations website.

Argus May 15 session

-7.84% close to close Open Argus

Details

News Market Reaction – WHWK

In the May 15 session, WHWK declined 7.84%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.8% in the session following this news. A negative reaction despite this routine i...

Analysis

The stock moved -7.8% in the session following this news. A negative reaction despite this routine investor conference appearance would have fit a pattern where news sometimes coincided with downside moves, such as after prior scientific or corporate updates. With shares already well above the 200-day moving average, some holders might have been sensitive to profit-taking. Recent financing activity and ongoing R&D losses could also have contributed to concerns about valuation and risk, potentially amplifying any downside response.

Key Figures

Event time: 3 PM ET Webcast replay period: 30 days

Event time

3 PM ET

Time of Stifel Virtual Targeted Oncology Forum fireside chat on May 19, 2026

Webcast replay period

30 days

Replay availability on Whitehawk Therapeutics investor relations website

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   Private placement

   24h Move

   +25.8%

   Announced approximately $87.5M private placement to extend ADC pipeline funding runway.

2. May 07

   Quarterly earnings

   24h Move

   -5.1%

   Reported Q1 2026 results with higher R&D spend and net loss amid ADC transition.

3. Apr 19

   Preclinical data

   24h Move

   +2.9%

   Presented AACR 2026 data showing tumor regressions and favorable ADC tolerability.

4. Apr 16

   Investor fireside chat

   24h Move

   -2.8%

   Announced CEO participation in a virtual fireside chat with webcast replay access.

5. Apr 10

   Target validation data

   24h Move

   -4.5%

   Presented SGO data confirming strong MUC16 expression supporting HWK‑016 development.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

antibody drug conjugate (adc)

1 terms

antibody drug conjugate (adc) medical

"to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments"

A antibody drug conjugate (ADC) is a targeted medicine that combines an antibody, which seeks out specific cells, with a potent drug payload so the treatment delivers its toxic effect directly to diseased cells while sparing most healthy tissue—think of a guided missile carrying a small explosive. Investors care because ADCs can offer breakthrough therapies with high market value, but their worth depends heavily on clinical trial results, manufacturing complexity and regulatory approval, which create both upside and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET.

A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics 
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact:
IR@whitehawktx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum-302773247.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Whitehawk Therapeutics (WHWK) present at the 2026 Stifel Virtual Targeted Oncology Forum?

Whitehawk Therapeutics will participate in a virtual fireside chat on May 19, 2026, at 3 PM ET. According to Whitehawk Therapeutics, this appearance is part of the 2026 Stifel Virtual Targeted Oncology Forum.

Who will represent Whitehawk Therapeutics (WHWK) at the 2026 Stifel Virtual Targeted Oncology Forum?

Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, will join the virtual fireside chat. According to Whitehawk Therapeutics, he will speak at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026.

How can investors watch Whitehawk Therapeutics' (WHWK) Stifel oncology forum webcast?

Investors can access a live webcast by visiting the Whitehawk Therapeutics investor relations website. According to Whitehawk Therapeutics, the webcast of the fireside chat will also be available for replay for about 30 days after the event.

Will a replay of Whitehawk Therapeutics' (WHWK) 2026 Stifel oncology fireside chat be available?

Yes, a replay will be available for approximately 30 days following the event. According to Whitehawk Therapeutics, investors can access the replay through the company’s investor relations website after the May 19, 2026 fireside chat.

What type of event is Whitehawk Therapeutics (WHWK) joining at the 2026 Stifel Virtual Targeted Oncology Forum?

Whitehawk Therapeutics will participate in a virtual fireside chat at the forum. According to Whitehawk Therapeutics, this session will be part of the 2026 Stifel Virtual Targeted Oncology Forum and will be webcast live for investors.